文献速递胸部肿瘤放疗泌尿生殖与妇科肿瘤放疗放疗物理与技术

体成分与前列腺癌或肺癌放疗相关副作用及健康相关生活质量的关联:REQUITE试验子分析

Associations between body composition and radiotherapy-related side-effects and health-related quality of life in patients with prostate or lung cancer: sub-analysis of the REQUITE trial.
PubMed 文献 · Radiother Oncol · 2026-06-27

该研究基于REQUITE前瞻性多中心数据集,评估CT衍生体成分指标与前列腺癌或肺癌患者放疗相关副作用及健康相关生活质量(HRQoL)的关联。结果显示体成分变量在12个终点中的9个位列前五重要预测因子,但加入模型后表观RMSE的改善虽具统计学意义却幅度很小,提示其作为探索性影像生物标志物需外部验证。

要点

  • 体成分变量在9/12终点中重要性排名前五,且9/12终点中排名高于BMI。
  • 加入体成分变量后表观/样本内RMSE降低具统计学意义(p<0.01)但幅度小。
  • CT衍生体成分作为探索性影像生物标志物,临床实施前需外部验证和临床意义增量价值证明。

核心结论

  • 体成分变量常位列放疗相关副作用和HRQoL的重要预测因子,但模型表观拟合的增量改善很小。
  • CT衍生体成分可能值得作为探索性影像生物标志物进一步研究,但临床实施前需外部验证和临床意义增量价值证明。

研究设计与样本

  • 基于REQUITE前瞻性多中心数据集,获取放疗计划CT、患者与疾病特征及治疗后24个月内临床医生和患者报告的副作用。
  • 前列腺癌和肺癌患者分别于L3和T12椎体水平分割骨骼肌和肌内脂肪组织,使用内部软件。
  • 采用标准化总平均毒性评分捕捉复合急性和晚期临床医生及患者报告的副作用和HRQoL,为所有终点开发有无体成分变量的梯度提升机模型,评估预测因子重要性排名和模型性能(RMSE)。

主要发现

  • 279例肺癌和848例前列腺癌患者纳入分析。
  • 体成分变量在12个终点中的9个位列前五重要变量。
  • 体成分变量在12个终点中的9个排名高于体重指数(BMI)。
  • 加入体成分变量与各终点表观/样本内RMSE的统计学显著(p<0.01)但小幅降低相关。

临床怎么用

  • CT衍生体成分可作为探索性影像生物标志物进一步研究,但尚不宜用于临床决策。
  • 临床实施前需外部验证并证明具有临床意义的增量价值。

局限性

  • 体成分变量带来的表观模型拟合增量改善很小。
  • 研究结论基于表观/样本内RMSE,需外部验证确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Body composition is emerging as a prognostic biomarker in cancer and may be associated with treatment tolerance, side-effects, and health-related quality of life (HRQoL). It can be measured from imaging routinely acquired during patient care. We evaluated whether body composition metrics were associated with radiotherapy-related side-effects and HRQoL in patients with prostate or lung cancer using a prospective multicentre dataset. METHODS: Radiotherapy planning computed tomography (CT) scans, patient and disease characteristics, and clinician- and patient-reported side-effects up to 24 months post-treatment were obtained from the REQUITE study. Skeletal muscle and intramuscular adipose tissue were segmented at the L3 and T12 vertebrae for prostate and lung patients respectively using in-house software. Standardised total average toxicity scores captured composite acute and late clinician- and patient-reported side-effects and HRQoL. Gradient boosted machine models were developed for all endpoints with and without body composition variables. Predictor importance rankings and model performance (root mean squared error (RMSE)) were assessed. RESULTS: 279 lung and 848 prostate patients were available for analysis. Body composition variables were ranked in the top five most important variables for 9 of 12 endpoints. Body composition variables were ranked higher than body mass index for 9 of 12 endpoints. Adding body composition variables was associated with statistically significant (p < 0.01) but small reductions in apparent/in-sample RMSE across endpoints. CONCLUSIONS: Body composition variables were frequently ranked among important predictors of radiotherapy-related side-effects and HRQoL, but their incremental improvement in apparent model fit was small. These findings suggest that CT-derived body composition may warrant further investigation as an exploratory imaging biomarker, but external validation and demonstration of clinically meaningful incremental value are required before clinical implementation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Vickers AJ, McSweeney DM, Choudhury A, et al. Associations between body composition and radiotherapy-related side-effects and health-related quality of life in patients with prostate or lung cancer: sub-analysis of the REQUITE trial. Radiother Oncol. 2026. PMID: 42364819. doi:10.1016/j.radonc.2026.111673

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。